Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;56(1):2408466.
doi: 10.1080/07853890.2024.2408466. Epub 2024 Oct 7.

Eosinophilic inflammation: a key player in COPD pathogenesis and progression

Affiliations
Review

Eosinophilic inflammation: a key player in COPD pathogenesis and progression

Yueh-Lun Lee et al. Ann Med. 2024 Dec.

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) remains a significant public health challenge due to its high morbidity and mortality rates. Emerging research has identified eosinophilic inflammation as a crucial factor in the pathogenesis and exacerbation of COPD, warranting a detailed exploration of its underlying mechanisms and therapeutic implications.

Objective: This review aims to elucidate the role of eosinophils in COPD, focusing on their contribution to airway remodeling, exacerbation frequency, and the inflammatory cascade.

Methods: We conducted a comprehensive literature review of recent studies that discuss the pathophysiological role of eosinophils in COPD and the clinical outcomes associated with modulating eosinophilic activity.

Results: Eosinophils contribute to COPD progression by releasing cytotoxic proteins and cytokines that intensify the inflammatory response and airway alterations. Targeting specific eosinophil-related cytokines with monoclonal antibodies or receptor antagonists may potentially reduce eosinophil counts, mitigate exacerbations, and improve patient outcomes.

Conclusion: Understanding eosinophilic involvement in COPD can facilitate the development of precision medicine approaches, offering more tailored and effective treatment options. Future research should continue to focus on the integration of eosinophil biomarkers in clinical practice to enhance therapeutic decisions and management strategies for COPD patients.

Keywords: Airway remodeling; asthma; emphysema; eosinophilia; precision medicine.

Plain language summary

Elevated eosinophil levels in COPD may be used to tailor treatment plans.Biologic therapies targeting eosinophils could be applied to manage eosinophilic COPD severity.Personalized treatment strategies based on eosinophil levels can enhance COPD management.Regular monitoring of eosinophil levels in COPD patients is crucial as it may influences treatment responses and disease progression.A deeper understanding of the role of eosinophils in COPD pathophysiology helps in making informed therapeutic decisions and developing targeted therapies.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Mechanism of Antigen-Induced alarmin release and subsequent immune response leading to airway hyperresponsiveness. Illustration of antigens inducing the release of alarmins including thymic stromal lymphopoietin (TSLP), eotaxin, and interleukin-33 (IL-33). The antigens are detected by dendritic cells, which in turn activate T-helper type 2 (Th2) cells and innate lymphoid cells (ILC2). The Th2 cells release cytokines, including IL-4, which promotes the infiltration of eosinophils. These eosinophils bind to vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on endothelial cells, facilitating their migration to the site of inflammation guided by eotaxin. This process leads to airway hyperresponsiveness, characterized by inflammation, fibrosis, and collagen deposition.

References

    1. Organization WH . Chronic obstructive pulmonary disease (COPD); 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pul....
    1. Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi: 10.1183/13993003.00239-2023. - DOI - PMC - PubMed
    1. Lombardi C, Berti A, Cottini M.. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42–53. doi: 10.1016/j.crimmu.2022.03.002. - DOI - PMC - PubMed
    1. George L, Brightling CE.. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016; 7(1):34–51. doi: 10.1177/2040622315609251. - DOI - PMC - PubMed
    1. Wu HX, Zhuo KQ, Cheng DY.. Prevalence and baseline clinical characteristics of eosinophilic chronic obstructive pulmonary disease: a meta-analysis and systematic review. Front Med (Lausanne). 2019;6:282. doi: 10.3389/fmed.2019.00282. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources